Sociedad Americana de Hirudoterapia

HmDestabilase

Hirudinaria manillensis destabilase / i-type lysozyme (Gao 2025) — isopeptidase + lysozyme activity, salivary-gland-upregulated on blood feeding.

Preclínico / mecanísticoLast updated: 2026-05-27 · Reviewed by ASH Editorial Board
Molecular weight of HmDestabilase compared with other characterized leech-derived compoundsHementerin80 kDaHementin80 kDaHementin-Like Protein (HLP-1)80 kDaLeech Collagenase70 kDaHaemadipsa yanyuanensis Progr…70 kDaLeech Apyrase67 kDaCalin65 kDaHyaluronidase60 kDaAntithrombin III binding prot…58 kDaCollagenolytic Fibrinolysin55 kDaLeech Thrombospondin-Like Pro…50 kDaHmDestabilase16 kDa
Molecular weight (kilodaltons) of HmDestabilase (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic
Page type
Compound profile
Evidence type
Hirudinaria manillensis destabilase / i-type lysozyme (Gao 2025) — isopeptidase + lysozyme activity, salivary-gland-upregulated on blood feeding.
Evidence level
In vitro
Drug vs leech
Recombinant (genetically expressed)
Safety domains
Bleeding

Clinical translation limit

HmDestabilase's in vitro isopeptidase / lysozyme activity does NOT establish clinical efficacy. No FDA-approved derivative exists; H. manillensis is not the FDA-cleared K040187 medicinal leech species.

Molecular Profile

Category
Fibrinolytic
Evidence tier
Preclinical
Molecular weight
16,000 Da
Source species
Hirudinaria manillensis
Discovered
2025 · Gao T et al.
HmDestabilase molecular structure

Biological Targets

  • isopeptide bonds in fibrin
  • bacterial peptidoglycan (lysozyme activity)

Key Citations

  1. Gao T et al. (2025), Protein Expr Purif · PMID 40107525

External Resources

    Related Fibrinolytic Compounds

    Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.